"WuXi AppTec"

- CONTENT--
WuXi AppTec Company Limited is a Chinese pharmaceutical company with operations in China, the United States and Western Europe. The headquarters are in Shanghai. The main specialization is the production of active ingredients of drugs and clinical trials. In the list of the largest public companies in the world, Forbes Global 2000 for 2022 took 1283rd place (1350th in net profit and 328th in market capitalization).

History
The company was founded in 2000 in Wuxi City, Jiangsu Province, originally called WuXi PharmaTech. In 2007, it placed its shares on the New York Stock Exchange. In 2008, the company acquired AppTec Laboratory Services with offices in Minnesota, Pennsylvania and Georgia, so the name was changed to WuXi AppTec. In 2009, a toxicology department was opened in Suzhou. In 2010, a factory was opened in Shanghai.

In 2015, WuXi Biologics separated from WuXi AppTec, which was listed on the Hong Kong Stock Exchange in 2017. In 2018, WuXi AppTec shares were listed on the Shanghai and Hong Kong stock exchanges. In 2021, Bristol Myers Squibb bought a factory in Switzerland.

Owners and management
The company was founded and continues to be headed by Li Ge, one of the richest Chinese billionaires, his fortune for 2022 was estimated at $ 8.3 billion.

Activities
WuXi AppTec conducts laboratory research for more than 4,000 customers in its laboratories in China and the United States, conducts clinical trials of new drugs necessary for their entry into the market, and is a contract manufacturer of drugs for other pharmaceutical companies. The main areas of activity are molecular biology, synthesis of oligonucleotides and peptides, cell transplantology, gene therapy, drug research, testing of medical devices, clinical research services.

The main research and production facilities of WuXi AppTec are located in China (Shanghai, Nantong, Suzhou, Changzhou, Wuxi, Nanjing, Tianjin, Chengdu, Wuhan, Beijing, Guangzhou), South Korea (Sonnam), USA (Philadelphia, Boston, Neutical, Atlanta, St. Paul, Austin, San Diego, San Francisco), Germany (Martinsrid), Great Britain (Oxford), Switzerland (Neuchatel) and Israel (Tel Aviv).

Subsidiaries
STA Pharmaceutical (China)
MedKey Med-Tech Development (China)
Jiecheng Med-Tech Development (China)
Kaipara Enterprises (Cyprus)
Klivia Investments (Poland)
Global Bond Investments (Hong Kong)
Chemdepo Inc. (USA)
Abgent Inc. (USA)
WuXi AppTec Holding Company (USA)
WuXi AppTec Sales (USA)
WuXi PharmaTech Investment Holdings (USA)
WuXi Advanced Therapies (USA)
WuXi AppTec UK (United Kingdom)
WuXi AppTec Biotechnology (China)
Wuxi AppTec Investment & Development (China)
WuXi AppTec Biomedical Investment Management

See also
List of the largest pharmaceutical companies in the world

Notes

Chinese Pharmaceutical Companies
Companies